Journal of Oncology Pharmacy Practice

Papers
(The H4-Index of Journal of Oncology Pharmacy Practice is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Safety of intramuscular tixagevimab-cilgavimab (Evusheld®) administration in patients at risk of iatrogenic haematoma due to haematological disorders26
Predictors of community pharmacists’ readiness to manage the effective and safe use of oral anticancer medicines in a developing setting26
Nivolumab-induced sensory ganglionopathy25
Investigation of 5-fluorouracil cardiotoxicity in combinational therapy: Influence of risk factors and demographics in a Pakistani population22
Perspectives toward biosimilars among oncologists: A Malaysian survey18
The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma14
Descriptive study of clinical pharmacist interventions in adult hospice and palliative care at a comprehensive oncology center in Jordan13
Acceptance of coronavirus disease 2019 vaccination by cancer patients in Cyprus: A cross-sectional study13
Multiple cardiotoxicities during osimertinib therapy12
Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors12
Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units11
Development and use of an innovative Gap Finding Tool to create a Pharmaceutical Care Model within a paediatric oncology setting11
Impact of a Pharmacist-Led Hypertension Management Program for Oral Chemotherapy in a Specialty Pharmacy Setting11
Vincristine induced fever in a child with embryonal rhadbomyosarcoma11
Residual chemotherapy drugs after flushing infusion lines11
Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib11
0.067300081253052